查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球散瞳治疗市场 - 2023-2030
市场调查报告书
商品编码
1374828

全球散瞳治疗市场 - 2023-2030

Global Mydriasis Treatment Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

瞳孔散大也称为瞳孔散大。当眼睛的黑色中心比正常情况大时，就会发生瞳孔散大。这种情况可能是由眼科检查中滴眼药水、任何药物或药物的副作用或外伤引起的。由于光线和情绪事件的变化，瞳孔会自然扩张，但异常的瞳孔扩张可能是由医疗状况引起的。瞳孔的正常大小在强光下为 2 至 4 毫米，在低光源下（散瞳）为 4 至 8 毫米。

而且，大多数时候，散瞳的瞳孔会自行恢復到正常大小。如果瞳孔突然放大、外伤后发生或引起头痛和神智不清，需要立即就医。散瞳的治疗包括戴太阳眼镜以降低对阳光的敏感度，特别是常使用光致变色镜片和偏光镜片，佩戴假体隐形眼镜以改善因外伤、药物滥用康復以及在某些情况下引起的瞳孔大小变化而导致的眼睛外观手术被认为是修復眼睛受伤造成的损伤。

市场动态：驱动因素

越来越多地采用眼科解决方案

眼科解决方案的日益普及预计将在预测期内推动市场发展。由于其非侵入性性质，眼药水（例如眼药水）通常最受瞳孔散大患者的青睐。这种偏好可以提高患者对处方治疗的依从性，从而获得更好的结果。由于采用率不断提高，许多公司都专注于开发眼科解决方案。

例如，2023年9月27日，Viatris Inc.发布消息称，美国食品药物管理局（FDA）批准0.75% RYZUMVI（酚妥拉明滴眼液）用于治疗肾上腺素激动剂（如去氧肾上腺素）或药物引起的药物引起的瞳孔散大。副交感神经阻断剂（例如托吡卡胺）。

此外，许多临床试验正在进行中，以开发新型眼科解决方案，这些解决方案在散瞳治疗方面显示出更好的效果。关于定期眼科检查和早期干预眼部疾病重要性的公众意识活动和教育倡议有助于采取更积极主动的眼保健方法。这反过来又推动了眼科解决方案主要用于治疗瞳孔散大的应用。

此外，许多监管部门的批准，例如 FDA 对新型眼科解决方案的批准，增加了患者对使用眼科解决方案的信任。例如，2023 年2 月13 日，Ocuphire Pharma, Inc. 获得了美国食品药物管理局(FDA) 的Nyxol（酚妥拉明眼用溶液0.75%）新药申请(NDA) 受理，用于治疗药物引起的瞳孔散大。

此外，散瞳盛行率的增加、新疗法的监管批准增加、临床试验和研究活动的增加、对散瞳、散瞳镜片及其治疗的认识的提高以及开发新疗法的技术进步预计将在预测期内推动市场。

限制

与手术相关的併发症、与眼药水相关的副作用、隐形眼镜的不适、治疗瞳孔散大的高成本以及缺乏更好和快速的治疗等因素预计将阻碍市场。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按治疗类型分類的片段
  • 按销售管道分類的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 眼科解决方案的采用率不断提高
    • 限制
      • 与手术相关的併发症
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 管道分析
  • 未满足的需求
  • 专利分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：按治疗类型

  • 太阳眼镜
    • 光致变色镜片
    • 偏光镜片
    • 其他的
  • 假体隐形眼镜
  • 手术
  • 药物滥用康復
  • 眼药水
    • 阿托品
    • 髓药酯
    • 后马托品
    • 去氧肾上腺素
    • 其他的
  • 其他的

第 8 章：按销售管道

  • 配销通路
    • 医院药房
    • 零售药局
    • 网路药局
  • 最终用户
    • 医院
    • 眼科诊所
    • 復健中心
    • 门诊手术中心
    • 学术及研究机构
    • 其他的

第 9 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 10 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 11 章：公司简介

  • Omeros Corporation
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Thea Laboratories
  • Ocuphire Pharma, Inc.
  • Alcon Inc.
  • Hoya Vision
  • Maui Jim USA, Inc.
  • Safilo Group SpA
  • Global Calcium Pvt Ltd
  • VISION EASE
  • ZEISS Group

第 12 章：附录

简介目录
Product Code: PH7347

Overview

Mydriasis is also known as dilated pupils. Mydriasis occurs when the black center of the eyes is larger than normal. The condition may be caused by dilating eye drops from an eye exam, the side effects from any drugs or medication or traumatic injury. Pupils naturally dilate due to changes in light and emotional events, but unusual pupil dilation could be the result of a medical condition. A pupil's normal size is 2 to 4 millimeters in bright light and 4 to 8 millimeters in dim light (dilated).

Moreover, most of the time, dilated pupils will back to normal size on their own. If pupils dilate suddenly, occur after a traumatic injury or cause headaches and confusion, need to seek medical attention immediately. The treatment of mydriasis includes wearing sunglasses to reduce sunlight sensitivity, especially photochromic lenses and polarized lenses are commonly used, wearing prosthetic contact lenses to improve the appearance of eyes as the result of varying pupil size caused by trauma, substance abuse rehabilitation and in some situations surgery is considered to repair eye damage from injury.

Market Dynamics: Drivers

Increasing adoption of ophthalmic solutions

The increasing adoption of ophthalmic solutions is expected to drive the market over the forecast period. Ophthalmic solutions, such as eye drops are often mostly preferred by mydriasis patients due to their non-invasive nature. This preference increases patient compliance with the prescribed treatments, leading to better outcomes. Due to the increasing adoption, many companies are focussing on developing ophthalmic solutions.

For instance, on September 27, 2023, Viatris Inc. released that the U.S. Food and Drug Administration (FDA) approved RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.

Moreover, many clinical trials are going on for the development of novel ophthalmic solutions that show better results in mydriasis treatment. Public awareness campaigns and educational initiatives about the importance of regular eye examinations and early intervention for eye conditions are contributing to a more proactive approach to eye care. This, in turn, drives the adoption of ophthalmic solutions mostly in the treatment of mydriasis.

Further, many regulatory approvals such as FDA approvals for novel ophthalmic solutions increase the trust in patients for the usage of ophthalmic solutions. For instance, on February 13, 2023, Ocuphire Pharma, Inc. cleared the U.S. Food and Drug Administration (FDA) acceptance for the New Drug Application (NDA) for Nyxol (phentolamine ophthalmic solution 0.75%) for the treatment of pharmacologically-induced mydriasis.

Further, the increasing prevalence of mydriasis, rising regulatory approvals for novel therapeutics, increasing clinical trials and research activities, increasing awareness about mydriasis, mydriatic lenses and their treatment and technological advancements in developing novel treatments are expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the surgery, side effects associated with the eye drops, the discomfort of the contact lenses, the high cost of the treatment of mydriasis and lack of better and quick treatment are expected to hamper the market.

Segment Analysis

The global mydriasis treatment market is segmented based on treatment type, sales channel and region.

The sunglasses segment accounted for approximately 42.2% of the mydriasis treatment market share

The sunglasses segment is expected to hold the largest market share over the forecast period. Sunglasses with photochromic lenses and polarized lenses are most commonly used to reduce sunlight sensitivity. Sometimes, individuals with mydriasis experience increased sensitivity to light, in such situations, sunglasses can help manage this sensitivity of the light by reducing the amount of light entering the eyes.

In addition, after certain eye surgeries or other mydriatic medical procedures, patients may be advised to wear sunglasses to protect the eyes from bright light and it reduces discomfort. While mydriatic sunglasses do not directly treat mydriasis, they can provide symptomatic relief by minimizing discomfort caused by bright light, glare, or intense sunlight.

Further, the wide availability and acceptability of the mydriatic sunglasses helps to hold the largest market share. In addition, their wide adoption also increases the demand for the sunglasses.

Geographical Analysis

North America accounted for approximately 39.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing research activities. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and medical device companies for developing novel ophthalmic solutions and advanced eyewear such as sunglasses and contact lenses. The presence of major players actively performing in clinical trials, leads to the launch of novel therapeutics and alternative treatment options for the treatment of mydriasis.

Furthermore, the increasing research activities especially in the United States also helps to develop more advanced therapeutics for the better management of the symptoms in the early stages. As the research activities increase, the therapeutics are developed more precisely by reducing the adverse effects and complications associated with the therapeutics and devices, which results in better patient outcomes.

Competitive Landscape

The major global players in the mydriasis treatment market include: Omeros Corporation, Thea Laboratories, Ocuphire Pharma, Inc., Alcon Inc., Hoya Vision, Maui Jim USA, Inc., Safilo Group S.p.A., Global Calcium Pvt Ltd, VISION EASE, ZEISS Group and among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global mydriasis treatment market. The pandemic created unprecedented challenges for pharmaceutical industries worldwide. During the pandemic, many clinical trials, research activities and regulatory approvals are temporarily disrupted or postponed due to the redirected focus on the COVID-19 pandemic and its related restrictions. The pandemic also disrupted the supply chain of these treatment medications and eyewear globally.

Market Segmentation

By Treatment Type

  • Sunglasses
    • Photochromic Lenses
    • Polarized Lenses
    • Others
  • Prosthetic Contact Lenses
  • Surgery
  • Substance Abuse Rehabilitation
  • Eye Drops
    • Atropine
    • Mydrilate
    • Homatropine
    • Phenylephrine
    • Others
  • Others

By Sales Channel

  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • End-User
    • Hospitals
    • Ophthalmic Clinics
    • Rehabilitation Centers
    • Ambulatory Surgical Centers
    • Academic and Research Institutes
    • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global mydriasis treatment market segmentation based on treatment type, sales channel and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of mydriasis treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global mydriasis treatment market report would provide approximately 53 tables, 49 figures, and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Sales Channel
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Adoption of Ophthalmic Solutions
    • 4.1.2. Restraints
      • 4.1.2.1. Complications Associated with the Surgery
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. Patent Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Sunglasses*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Photochromic Lenses
    • 7.2.4. Polarized Lenses
    • 7.2.5. Others
  • 7.3. Prosthetic Contact Lenses
  • 7.4. Surgery
  • 7.5. Substance Abuse Rehabilitation
  • 7.6. Eye Drops
    • 7.6.1. Atropine
    • 7.6.2. Mydrilate
    • 7.6.3. Homatropine
    • 7.6.4. Phenylephrine
    • 7.6.5. Others
  • 7.7. Others

8. By Sales Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 8.1.2. Market Attractiveness Index, By Sales Channel
  • 8.2. Distribution Channel*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Hospital Pharmacies
    • 8.2.4. Retail Pharmacies
    • 8.2.5. Online Pharmacies
  • 8.3. End-User
    • 8.3.1. Hospitals
    • 8.3.2. Ophthalmic Clinics
    • 8.3.3. Rehabilitation Centers
    • 8.3.4. Ambulatory Surgical Centers
    • 8.3.5. Academic and Research Institutes
    • 8.3.6. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. UK
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Omeros Corporation*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Thea Laboratories
  • 11.3. Ocuphire Pharma, Inc.
  • 11.4. Alcon Inc.
  • 11.5. Hoya Vision
  • 11.6. Maui Jim USA, Inc.
  • 11.7. Safilo Group S.p.A.
  • 11.8. Global Calcium Pvt Ltd
  • 11.9. VISION EASE
  • 11.10. ZEISS Group

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us